Samsung Biologics announced on the 9th through a disclosure that it has signed a contract manufacturing organization (CMO) agreement worth KRW 1.8001 trillion (USD 1.29464 billion) with a U.S.-based pharmaceutical company. This is the second-largest contract following the approximately KRW 2 trillion agreement signed with a European company in January. The contract period extends until December 31, 2029. Due to confidentiality agreements, the client and product names will not be disclosed.

With this contract, Samsung Biologics' cumulative order amount for this year has been recorded at KRW 5.2435 trillion, approaching last year's annual orders (KRW 5.4035 trillion) in just eight months. Since its founding, the total cumulative order amount has surpassed KRW 27 trillion. The company is being evaluated as having proven its competitiveness by securing consecutive large-scale contracts amid increasing management uncertainties in the industry, such as global economic slowdown and tariff issues.

The proactive enhancement of production capacity to meet the increasing demand for biopharmaceuticals is also progressing smoothly. Plant 5, which began full operation in April this year, is a state-of-the-art facility with a capacity of 180,000 liters, incorporating the best practices of Plants 1 to 4. The company has secured the world's largest production capacity of 784,000 liters. In terms of quality, it has obtained a total of 382 manufacturing approvals (as of September 2025) from major global regulatory agencies in the U.S., Europe, and Japan. The number of approvals is increasing with the expansion of production capacity, and the inspection pass rate by regulatory agencies remains at the highest level in the industry.

Meanwhile, Samsung Biologics plans to accelerate its penetration into the global market by expanding its major customer base from the existing 'Top 20' to 'Top 40' companies. It is actively participating in major global pharmaceutical and biotech events such as the JP Morgan Healthcare Conference and the BIO International Convention to showcase its technology and competitiveness and to expand contact points with potential customers.

Popular News